Andelen af patienter som seponerede behandling på grund af bivirkninger, var 3, 4% for abataceptbehandlede patienter og 2, 2% for placebobehandlede.
5 The proportion of patients who discontinued treatment due to ADRs was 3.4% for abatacept-treated patients and 2.2% for placebo-treated patients.